Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 4, 2010, Pages 810-816

  Sinitsky, Daniel M ^a   Lemberg, Daniel A ^a   Leach, Steven T ^b   Bohane, Timothy D ^a,b   Jackson, Reuben ^a   Day, Andrew S ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Children; Crohn's disease; Infliximab

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PARACETAMOL; PROMETHAZINE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANTHROPOMETRY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LEUKOCYTE COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT RESPONSE;

EID: 77950112227     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06195.x     Document Type: Article

References (33)

1. Borrelli O, Bascietto C, Viola F et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 2004 36 : 342 347.
2. Lichtenstein GR. Approach to steroid-dependent and steroid-refractory Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 2001 33 (Suppl. 1 S27 35.
3. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006 4 : 621 630.
4. Yang Y-X, Lichtenstein GR. Corticosteroids in Crohn's disease. Am. J. Gastroenterol. 2002 97 : 803 823.
5. Baldassano R, Braegger CP, Escher JC et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 2003 98 : 833 838.
6. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994 35 : 360 362.
7. Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterology 2000 119 : 1132 1147.
8. de Ridder L, Escher JC, Bouquet J et al. Infliximab therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in The Netherlands. J. Pediatr. Gastroenterol. Nutr. 2004 39 : 46 52.
9. Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 2006 42 : 40 5.
10. Cezard J-P, Nouaili N, Talbotec C et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 2003 36 : 632 636.
11. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007 132 : 863 873 quiz 1165-6.
12. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J. Pediatr. 2000 137 : 192 196.
13. Lamireau T, Cezard J-P, Dabadie A et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm. Bowel Dis. 2004 10 : 745 750.
14. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr., Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. 2001 35 : 823 828.
15. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am. J. Gastroenterol. 2003 98 : 104 111.
16. de Ridder L, Benninga MA, Taminiau JAJM, Hommes DW, van Deventer SJH. Infliximab use in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007 45 : 3 14.
17. Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004 53 : 849 853.
18. Mackey AC, Green L, Liang L-C, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007 44 : 265 267.
19. Wei SZ, Liu TH, Wang DT, Cao JL, Luo YF, Liang ZY. Hepatosplenic gammadelta T-cell lymphoma. World J. Gastroenterol. 2005 11 : 3729 3734.
20. Hyams J, Markowitz J, Otley A et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J. Pediatr. Gastroenterol. Nutr. 2005 41 : 416 421.
21. Loonen HJ, Griffiths AM, Merkus MP, Derkx HH. A critical assessment of items on the Pediatric Crohn's Disease Activity Index. J. Pediatr. Gastroenterol. Nutr. 2003 36 : 90 5.
22. Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology 1999 116 : 527 531.
23. Afzal NA, Ozzard A, Keady S, Thomson M, Heuschkel R. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn's Disease. Dig. Dis. Sci. 2007 52 : 3329 3333.
24. Walters TD, Gilman AR, Griffiths AM. Infliximab therapy restores normal growth in children with chronically active severe Crohn disease refractory to immunomodulatory therapy. J. Pediatr. Gastroenterol. Nutr. 2005 40 : 646.
25. Diamanti A, Basso MS, Gambarara M et al. Positive impact of blocking tumor necrosis factor α on the nutritional status in pediatric Crohn's disease patients. Int. J. Colorectal. Dis. 2009 24 : 19 25.
26. D'Haens G, Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999 116 : 1029 1034.
27. Friesen CA, Calabro C, Christenson K et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2004 39 : 265 269.
28. Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007 96 : 128 130.
29. Jacobstein DA, Markowitz JE, Kirschner BS et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. 2005 11 : 442 446.
30. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment. Pharmacol. Ther. 2003 17 : 75 84.
31. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
32. Colombel J-F, Loftus EV Jr., Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
33. Palm Ø, Bernklev T, Moum B, Gran JT. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J. Rheumatol. 2005 32 : 1755 1759.